EQS-Adhoc: LR Health & Beauty SE: PRELIMINARY RESULTS FOR FINANCIAL YEAR 2025 / TARGETED EQUITY CONTRIBUTION / TARGETED RESTRUCTURING OF THE 2024/2028 BONDS

Disclosure of an inside information according to Art. 17 of the Regulation (EU) No. 596/2014 (Market Abuse Regulation – MAR)

LR HEALTH & BEAUTY SE: PRELIMINARY RESULTS FOR FINANCIAL YEAR 2025 / TARGETED EQUITY CONTRIBUTION / TARGETED RESTRUCTURING OF THE 2024/2028 BONDS

Ahlen, 23 January 2026 – Today, based on the preliminary financial results for the financial year 2025, the Management Board of LR Health & Beauty SE (the “Company”) expects an EBITDA¹ reported of around EUR 16 million for the financial year 2025 (previously expected to be between EUR 17.0 million and EUR 20.0 million). At the same time, the Management Board of the Company expects sales (revenue from goods sold) of around EUR 277 million for the full year 2025 (previously expected to be between EUR 276 million and EUR 281 million).

Also today, EY-Parthenon announced the completion of a draft IDW S 6 restructuring opinion in respect of the Company. Pursuant to the analysis set out in that draft restructuring opinion, the Company will for the financial year 2028 achieve an EBITDA¹ of EUR 27.3 million and sales of EUR 281.5 million in the sensitivity case, and an EBITDA¹ of EUR 31.4 million as well as sales of EUR 284.7 million in the management case.

Against this background, the Company decided today to enter into discussions with its shareholder and with the bondholders of the Company’s outstanding 2024/2028 bonds (ISIN: NO0013149658) (the “Bonds”). The aim of such discussions is to explore the possibility of a financial restructuring of the Company comprising (the following measures together the “Restructuring Measures”):

• an equity contribution from the Company’s shareholder in the amount of EUR 10 million for financing of the Company’s operating business; and
• bondholder approval of certain amendments to the terms and conditions of the Bonds (through a new written procedure under the Bonds) in respect of:
  • a write-down of 55 % of the nominal amount of the Bonds on a pro rata basis (including the capitalised interest in respect of the interest payments under the Bonds due in November 2025 and February 2026), after which the outstanding nominal amount under the Bonds will amount to EUR 61.3 million;
  • an extension of the term of the Bonds until 31 December 2029;
  • a deferral of the interest payments under the Bonds due in November 2025 and February 2026 (on a capitalising basis and subject to write-down mechanism set out above) and other interest payments under the Bonds due during the period up to and including May 2027 (on a capitalising basis) until the Bonds’ extended maturity date;
  • cash sweep mechanisms for excess cash over a EUR 15 million threshold; and
  • a contractual right (Besserungsschein) for the bondholders to receive cash in an aggregate amount of up to EUR 74.9 million (being equal to the written down amount) out of any excess cash received out of a refinancing of the Bonds.

The holders of the Bonds shall be entitled to participate in the refinancing process.

If the Restructuring Measures cannot be implemented, it is currently assumed that the holders of the Bond could expect an insolvency quota of around 6% in an insolvency liquidation scenario.


¹EBITDA, based on IFRS as used in the unaudited consolidated interim report of the Company for Q3 2025 which can be found on the Company’s website at https://media.lrworld.com/IR/Interim_Report_Q3_2025.pdf.


IR contact:

cometis AG
Thorben Burbach
Unter den Eichen 7 | Gebäude D
65195 Wiesbaden
Phone: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-mail: burbach@cometis.de

2265422  23-Jan-2026 CET/CEST